Episode
Phase 3 Trial Reduces Risk of Progression in Metastatic Prostate Cancer
- Podcast
- Advances in Care
- Published
- Mar 5, 2026
- Duration seconds
- 954
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/advances-in-care-6039100/episodes/phase-3-trial-reduces-risk-of-progression-in-metastatic-prostate-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/advances-in-care-6039100/phase-3-trial-reduces-risk-of-progression-in-metastatic-prostate-cancer.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Advances in Care host Erin Welsh is joined by Dr. Scott Tagawa, medical oncologist at NewYork-Presbyterian and director of the Genitourinary Oncology Program at Weill Cornell Medicine, to talk about the latest developments in prostate cancer care. Dr. Tagawa recently led a Phase III randomized trial– called PSMAddition–to assess targeted radioligand therapy in men with hormone-sensitive metastatic prostate cancer, which yielded notable declines in PSA levels and slowed cancer progression by 28%. The use of this therapeutic earlier in treatment as opposed to a last-line defense has the potential to redefine the standard of care and improve outcomes for patients with metastatic prostate cancer.